Skip to main content

Advertisement

Figure 4 | Arthritis Research & Therapy

Figure 4

From: NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor

Figure 4

Effect of dehydroxymethylepoxyquinomicin on serum factors involved in osteoclastogenesis. Effect of dehydroxymethylepoxyquinomicin (DHMEQ) on serum levels of (a) osteoprotegerin (OPG), (b) soluble receptor activator of NF-κB ligand (sRANKL), (c) sRANKL/OPG ratio and (d) macrophage colony-stimulating factor. Serum levels of these cytokines in individual arthritic mice 3 hours after the last treatment with vehicle alone (n = 13) or with DHMEQ (n = 12), and in age-matched normal mice (n = 4–6), were determined by ELISA. Horizontal lines represent the median. Data were analyzed by the Mann-Whitney test. P < 0.05 was considered significant; ns, not significant.

Back to article page